Adult T-cell leukemia–lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute lymphoblastic leukemia (T-ALL). This form of therapy used genome editing ...

Despite major advances in immunotherapy—including the 2025 Nobel Prize in Physiology or Medicine recognizing advances in peripheral immune tolerance—progress against leukemia has remained limited.

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

This study shows that TGF-β triggers the nuclear translocation of HBZ specifically in ATL cells from patients with ATL, not in HTLV-1–infected cells from asymptomatic carriers. JunB interacts with HBZ ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in ...

Imagine finding a “cure” for a type of cancer that’s long enjoyed the reputation of being aggressive and incurable. Thanks to recent trials, it’s no longer a dream — a groundbreaking scientific ...

The research is happening at Roswell Park Comprehensive Cancer Center.